(精编)brenner may 19教学课件.pptVIP

RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the AII Antagonist Losartan;Angiotensin II Drives Pathology in Hypertension ;Clinical Endpoint Data for ESRD in Type 2 Diabetes with ACE Inhibitors Are Lacking;Controlling the Course of Renal Disease with Losartan;Losartan compared to placebo (alone or in combination with conventional antihypertensive therapy*) in patients with Type 2 diabetes and nephropathy will Increase the time to first event and decrease the incidence of cardiovascular morbidity/mortality Reduce protein